ZAHID KOCAK, Mehmet. Comment on ‘Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab’. Acta Oncologica, [S. l.], v. 60, n. 4, p. 564–565, 2021. DOI: 10.1080/0284186X.2021.1889028. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/21487. Acesso em: 31 may. 2026.